Annals of Oncology Advance Access originally published online on May 3, 2005
Annals of Oncology 2005 16(8):1311-1319; doi:10.1093/annonc/mdi246
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
1 University Hospital Dresden, Germany; 2 Mayo Clinic, Rochester, MN, USA; 3 Hospital Oldenburg, Germany
* Correspondence to: Prof. C.-H. Köhne, Hospital Oldenburg, Department of Oncology and Hematology, Dr.-Eden-Str. 10, 26133 Oldenburg, Germany. Tel: +49-441-403-2611; Fax: +49-441-403-2654; Email: onkologie{at}klinikum-oldenburg.de
Background:: Long-term survival is reported in patients with liver metastases of colorectal cancer. Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published.
Methods:: We analysed all published or presented trials and retrospective studies that report the rate of objective response and the rate of resection of initially unresectable metastases to correlate objective response and the rate of resection of metastases.
Results:: In studies that enrolled patients with metastases confined to the liver, 24–54% of patients were resected following chemotherapy, compared to 1–26% of patients in trials that included non-selected patients with metastatic colorectal cancer. A strong correlation was found between response rates and the resection rate in studies with patients with isolated liver metastases (r = 0.96, P=0.002). Likewise, in studies with non-selected patients, the resection rate of metastases also was associated with the objective response rate (r = 0.74, P <0.001).
Conclusions:: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases. Resectability is a novel endpoint focusing on the curative potential of treatment compared with classical endpoints of response or progression-free survival that are important if palliation is the aim. Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams.
Key words: colorectal cancer, liver metastases, neoadjuvant chemotherapy, resection
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. G. W. Scheer, C. E. J. Sloots, G. J. van der Wilt, and T. J. M. Ruers Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases Ann. Onc., July 28, 2008; (2008) mdn398v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Power and G. D. Leonard Hepatic Arterial Infusion: A Treatment at the "End of an Era"? J. Clin. Oncol., May 20, 2008; 26(15): 2597 - 2598. [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann. Onc., May 1, 2008; 19(5): 920 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Van Buren II, A. D. Yang, N. A. Dallas, M. J. Gray, S. J. Lim, L. Xia, F. Fan, R. Somcio, Y. Wu, D. J. Hicklin, et al. Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model J. Clin. Oncol., April 10, 2008; 26(11): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Andres, P. E. Majno, P. Morel, L. Rubbia-Brandt, E. Giostra, P. Gervaz, S. Terraz, A. S. Allal, A. D. Roth, and G. Mentha Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score Ann. Surg. Oncol., January 1, 2008; 15(1): 134 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Vauthey Colorectal Liver Metastases: Treat Effectively Up Front and Consider the Borderline Resectable J. Clin. Oncol., October 10, 2007; 25(29): 4524 - 4525. [Full Text] [PDF]
|
|
|
|
|
|
R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M.-P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, et al. Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy J. Clin. Oncol., October 10, 2007; 25(29): 4593 - 4602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Liersch, J. Meller, M. Bittrich, B. Kulle, H. Becker, and D. M. Goldenberg Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group Ann. Surg. Oncol., September 1, 2007; 14(9): 2577 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest J. Clin. Oncol., May 1, 2007; 25(13): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. M. Ruers, J. J. Joosten, B. Wiering, B. S. Langenhoff, H. M. Dekker, T. Wobbes, W. J. G. Oyen, P. F. M. Krabbe, and C. J. A. Punt Comparison Between Local Ablative Therapy and Chemotherapy for Non-Resectable Colorectal Liver Metastases: A Prospective Study Ann. Surg. Oncol., March 1, 2007; 14(3): 1161 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Abdalla, R. Adam, A. J. Bilchik, D. Jaeck, J.-N. Vauthey, and D. Mahvi Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement Ann. Surg. Oncol., October 1, 2006; 13(10): 1271 - 1280. [Full Text] [PDF]
|
|
|
|
 |
|
 O J Garden, M Rees, G J Poston, D Mirza, M Saunders, J Ledermann, J N Primrose, and R W Parks Guidelines for resection of colorectal cancer liver metastases Gut, August 1, 2006; 55(suppl_3): iii1 - iii8. [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges J. Clin. Oncol., July 20, 2006; 24(21): 3325 - 3327. [Full Text] [PDF]
|
|
|
|
|
|
G. Poston, R. Adam, and J.-N. Vauthey Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer? J. Clin. Oncol., June 20, 2006; 24(18): 2702 - 2706. [Full Text] [PDF]
|
|
|
|
|
|
G. Chong and D. Cunningham Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066. [Full Text] [PDF]
|
|